--- title: "Venus Concept (VERO.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/VERO.US.md" symbol: "VERO.US" name: "Venus Concept" industry: "Health Care Equipment" datetime: "2026-04-17T03:14:35.228Z" locales: - [en](https://longbridge.com/en/quote/VERO.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/VERO.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/VERO.US.md) --- # Venus Concept (VERO.US) ## Company Overview Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, a portable and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF combined with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, flanks, back, and thighs in individuals with a body mass index BMI of 30 or less; Venus Glow, a Motorized dermabrasion device used to improve skin appearance; and NeoGraft, a hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. | Item | Detail | |------|--------| | Industry | Health Care Equipment | | Exchange | US Market | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-04-16T04:30:18.000Z **Overall: D (0.68)** **Industry**: Health Care Equipment | Metric | Value | |--------|-------| | Industry Ranking | 157 / 183 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -12.39% | | | Net Profit YoY | -8.91% | | | P/B Ratio | 0.00 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 577276.28 | | | Revenue | 58876000.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -854.61% | E | | Profit Margin | -92.76% | E | | Gross Margin | 64.00% | A | | Revenue YoY | -12.39% | E | | Net Profit YoY | -8.91% | D | | Total Assets YoY | -14.74% | E | | Net Assets YoY | -70.51% | E | | Cash Flow Margin | 37.45% | C | | OCF YoY | -12.39% | E | | Turnover | 0.88 | B | | Gearing Ratio | 94.91% | E | ```chart-data:radar { "title": "Longbridge Financial Score - Venus Concept", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-12.39%", "rating": "" }, { "name": "Net Profit YoY", "value": "-8.91%", "rating": "" }, { "name": "P/B Ratio", "value": "0.00", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "577276.28", "rating": "" }, { "name": "Revenue", "value": "58876000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-854.61%", "rating": "E" }, { "name": "Profit Margin", "value": "-92.76%", "rating": "E" }, { "name": "Gross Margin", "value": "64.00%", "rating": "A" }, { "name": "Revenue YoY", "value": "-12.39%", "rating": "E" }, { "name": "Net Profit YoY", "value": "-8.91%", "rating": "D" }, { "name": "Total Assets YoY", "value": "-14.74%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-70.51%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "37.45%", "rating": "C" }, { "name": "OCF YoY", "value": "-12.39%", "rating": "E" }, { "name": "Turnover", "value": "0.88", "rating": "B" }, { "name": "Gearing Ratio", "value": "94.91%", "rating": "E" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -0.01 | 48/183 | - | - | - | | PB | 0.21 | 5/183 | 1.90 | 1.34 | 0.88 | | PS (TTM) | 0.01 | 4/183 | 0.07 | 0.06 | 0.04 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Delcath (DCTH.US) | C | A | B | A | A | A | | 02 | Abbott Laboratories (ABT.US) | B | C | C | C | B | B | | 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B | | 04 | Stryker (SYK.US) | A | B | C | C | B | B | | 05 | Boston Scientific (BSX.US) | B | B | C | C | B | B | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VERO.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VERO.US/norm.md) - [Related News](https://longbridge.com/en/quote/VERO.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VERO.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**